|
Proposed biomarker | Biological role | Serum level in PE compared to normotensive pregnancy | Type of study | Positive predictive value | References |
|
Soluble fms-like tyrosine kinase 1 (sFlt-1) | Anti-angiogenic factor | Higher | Case-control | No | [24, 46–51] |
Nested case-control | No | [52, 53] |
Cross-sectional case-control | No | [54–56] |
Longitudinal case-control | No | [57, 58] |
Prospective cohort | No | [59, 60] |
Yes | [61] |
Prospective nested case-control | No | [62] |
|
Placental growth factor (PlGF) | Angiogenic factor | Lower | Case-control | No | [24, 46, 48, 50, 51] |
Yes | [63–65] |
Nested case-control | No | [52, 53, 66] |
Cross-sectional case-control | No | [54–56] |
Longitudinal case-control | No | [57, 58, 67] |
Yes | [68] |
Prospective cohort | No | [59, 60] |
Yes | [61] |
Prospective nested case-control | No | [62] |
Prospective longitudinal case-control | No | [69] |
Longitudinal cohort | No | [70] |
Longitudinal cross-sectional | No | [71, 72] |
|
Asymmetric Dimethyl-Arginine (ADMA) | Biochemical degradation product | Higher | Case-control | No | [73–77] |
Longitudinal case-control | No | [78–82] |
Cross-sectional case-control | No | [83, 84] |
|
Soluble Endoglin (sEng) | Modulator of transforming growth factor (TGF)-β signalling | Higher | Longitudinal case-control | No | [58] |
Cross-sectional case-control | No | [85, 86] |
Nested case-control | No | [87, 88] |
Retrospective | No | [89] |
Prospective | No | [90] |
Case-control | No | [91] |
|
Placental Protein 13 (PP-13) | Lysophospholipase activity | Higher | Longitudinal case-control | No | [92, 93] |
Nested case-control | No | [94–98] |
Case-control | No | [99] |
|
P-Selectin | Calcium-dependent receptor | Higher | Cross-sectional case-control | No | [100–105] |
Yes | [106] |
Longitudinal case-control | No | [107] |
Yes | [108] |
|
Adrenomedullin | Vasodilator | Higher | Cross-sectional case-control | No | [109] |
|
A Disintegrin and Metalloprotease 12 (ADAM12) | Cell-cell and cell-matrix interaction protease | Lower | Retrospective case-control | No | [110] |
Cross-sectional case-control | No | [111, 112] |
|
Pentraxin 3 (PTX3) | Angiogenesis and inflammation factor | Higher | Cross-sectional case-control | No | [113, 114] |
|
Pregnancy-Associated Plasma Protein A (PAPP-A) | Metalloproteinase that cleaves insulin-like growth factor binding proteins (IGFBPs) | Lower | Case-control | Yes | [64] |
Nested case-control | No | [98] |
Cross-sectional case-control | No | [115–118] |
Retrospective cohort | No | [119–122] |
Prospective cohort | No | [123] |
|
Nicotinamide Phosphoribosyltransferase; Visfatin | Enzyme involved in nicotinamide metabolism | Both | Cross-sectional case-control | No | [124] |
|
Cell free DNA | N.A | Higher | Cross-sectional case-control | No | [125–127] |
|
Cell-free foetal DNA | N.A. | Higher | Cross-sectional case-control | No | [127–129] |
Nested case-control | No | [130, 131] |
Prospective | No | [132, 133] |
|